Prostate Cancer
An international team has discovered that prostate cancer cells depend on two enzymes, PDIA1 and PDIA5, for survival and resistance to therapy. Blocking these enzymes destabilizes the androgen receptor, leading to cancer cell death and improved drug efficacy. The findings, published in PNAS, suggest new ways to combat advanced prostate cancer.
An Ruwaito ta hanyar AI
A phase III trial has shown that adding niraparib to standard prostate cancer therapy significantly delays disease progression in men with specific DNA repair gene mutations. The AMPLITUDE study, involving 696 men across 32 countries, reported a 37% reduced risk of cancer growth overall and 48% in BRCA-mutated cases. This marks a step toward precision medicine for advanced prostate cancer.